1''-Methoxyerythrinin CCAS# 221002-11-5 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 221002-11-5 | SDF | Download SDF |
PubChem ID | 102004641 | Appearance | Powder |
Formula | C21H20O7 | M.Wt | 384.4 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S,3S)-4-hydroxy-6-(4-hydroxyphenyl)-2-(2-hydroxypropan-2-yl)-3-methoxy-2,3-dihydrofuro[3,2-g]chromen-5-one | ||
SMILES | CC(C)(C1C(C2=C(O1)C=C3C(=C2O)C(=O)C(=CO3)C4=CC=C(C=C4)O)OC)O | ||
Standard InChIKey | RAFBVESTDOVORR-PMACEKPBSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
1''-Methoxyerythrinin C Dilution Calculator
1''-Methoxyerythrinin C Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6015 mL | 13.0073 mL | 26.0146 mL | 52.0291 mL | 65.0364 mL |
5 mM | 0.5203 mL | 2.6015 mL | 5.2029 mL | 10.4058 mL | 13.0073 mL |
10 mM | 0.2601 mL | 1.3007 mL | 2.6015 mL | 5.2029 mL | 6.5036 mL |
50 mM | 0.052 mL | 0.2601 mL | 0.5203 mL | 1.0406 mL | 1.3007 mL |
100 mM | 0.026 mL | 0.1301 mL | 0.2601 mL | 0.5203 mL | 0.6504 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Guaiacol glycidyl ether
Catalog No.:BCC8992
CAS No.:2210-74-4
- Lumiracoxib
Catalog No.:BCC4440
CAS No.:220991-20-8
- Antalarmin hydrochloride
Catalog No.:BCC7480
CAS No.:220953-69-5
- 13-O-Deacetyltaxumairol Z
Catalog No.:BCN4945
CAS No.:220935-39-7
- 13-O-Cinnamoylbaccatin III
Catalog No.:BCN7344
CAS No.:220932-65-0
- GW5074
Catalog No.:BCC4391
CAS No.:220904-83-6
- 2,3-O-Isopropylidenyl euscaphic acid
Catalog No.:BCN4944
CAS No.:220880-90-0
- Thunalbene
Catalog No.:BCN3688
CAS No.:220862-05-5
- 7-Methoxy-8-Hydroxy-4-Methylcoumarin
Catalog No.:BCC8291
CAS No.:22084-94-2
- NG,NG-Dimethylarginine dihydrochloride
Catalog No.:BCN1485
CAS No.:220805-22-1
- Aminopurvalanol A
Catalog No.:BCC7249
CAS No.:220792-57-4
- Aquifoliunine E-III
Catalog No.:BCN3096
CAS No.:220751-20-2
- 1alpha,4beta,10beta-Trihydroxyguaia-2,11(13)-dien-12,6alpha-olide
Catalog No.:BCN7483
CAS No.:221148-94-3
- Erysubin A
Catalog No.:BCN4946
CAS No.:221150-18-1
- Erysubin B
Catalog No.:BCN4947
CAS No.:221150-19-2
- Glyoxalase I inhibitor
Catalog No.:BCC1598
CAS No.:221174-33-0
- Z-Lys-OH
Catalog No.:BCC2764
CAS No.:2212-75-1
- Z-Lys(Boc)-OH.DCHA
Catalog No.:BCC2591
CAS No.:2212-76-2
- 1-Naphthyl PP1
Catalog No.:BCC3893
CAS No.:221243-82-9
- 1-NM-PP1
Catalog No.:BCC4306
CAS No.:221244-14-0
- 7,4'-Di-O-methylapigenin 5-O-xylosylglucoside
Catalog No.:BCN1484
CAS No.:221257-06-3
- Lethedoside A
Catalog No.:BCN4948
CAS No.:221289-20-9
- Lethedioside A
Catalog No.:BCN5046
CAS No.:221289-31-2
- Leptocarpinine
Catalog No.:BCN3730
CAS No.:221347-12-2
Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection.[Pubmed:29024739]
Pharmacol Ther. 2018 Mar;183:118-126.
Hepatitis C virus (HCV) is a global health problem, because infection frequently leads to chronic hepatitis C eventually progressing to liver cirrhosis and liver cancer. Improved insights into the HCV replication cycle and the role of HCV non-structural proteins have recently enabled to identify drugs directly acting on specific HCV target structures. Agents from three drug classes have been developed and approved by the health authorities. Combinations of two or more drugs from different classes achieve high (>90%) HCV clearance rates and are well tolerated. This interferon-free DAA (direct antiviral agent) therapy has revolutionized antiviral therapy in hepatitis C so that successful hepatitis C treatment can be offered to virtually all patients irrespective of their co-morbidity. This review provides an overview over currently approved regimens and outlines their use in clinical practice. In addition potential short-comings of the current therapeutic options such as drug-drug interactions and selection of viral resistance are addressed. DAA combination therapy has the potential to obtain global control over hepatitis C. However, easy access to DAAs, availability of reliable HCV diagnostics, and affordable costs remain still important goals, which must be reached to globally eliminate hepatitis C.
Comparative analysis of clinics, pathologies and immune responses in BALB/c and C57BL/6 mice infected with Streptobacillus moniliformis.[Pubmed:29024796]
Microbes Infect. 2018 Feb;20(2):101-110.
Streptobacillus (S.) moniliformis is a rat-associated zoonotic pathogen that occasionally causes disease in other species. We investigated the working hypothesis that intranasal infection might lead to different immune responses in C57BL/6 and BALB/c mice associated with distinct pathologies. This study confirmed with 75% mortality the known high susceptibility of C57BL/6 mice to Streptobacillus moniliformis infection in comparison to BALB/c mice which did not develop signs of disease. Main pathologies in C57BL/6 mice were purulent to necrotizing lymphadenitis and pneumonia. Significant seroconversion was recorded in surviving mice of both strains. Differentiation of IgG-subclasses revealed mean ratios of IgG2b to IgG1 below 0.5 in sera of all mice prior to infection and of BALB/c mice post infection. In contrast, C57BL/6 mice had a mean IgG2b/IgG1 ratio of 2.5 post infection indicating a Th1 immune response in C57BL/6 versus a Th2 response in BALB/c mice. Evaluation of different sentinel systems revealed that cultural and serological investigations of these animals might not be sufficient to detect infection. In summary, an intranasal S. moniliformis infection model in C57BL/6 mice leading to purulent to necrotizing inflammations in the lung, the lymph nodes and other organs associated with a Th1 immune response is described.
Pubertally Initiated High-Fat Diet Promotes Mammary Tumorigenesis in Obesity-Prone FVB Mice Similarly to Obesity-Resistant BALB/c Mice.[Pubmed:29024822]
Transl Oncol. 2017 Dec;10(6):928-935.
Premenopausal breast cancer is associated with increased animal fat consumption among normal-weight but not overweight women. Our previous findings in obesity-resistant BALB/c mice showed that a diet high in saturated animal fat (HFD) promotes mammary tumorigenesis in both DMBA carcinogenesis and Trp53-null transplant models. Having made these observations in BALB/c mice, which have very modest HFD weight gain, we determined the effects of HFD in FVB mice, which gain significant weight on HFD. Three-week-old FVB mice fed a low-fat diet or HFD were subjected to 7,12-dimethylbenz[a]anthracene-induced carcinogenesis. Like BALB/c mice, HFD promoted mammary tumorigenesis. Development of tumors largely occurred prior to mice becoming obese, indicating the role of animal-derived HFD rather than resulting obesity in tumor promotion. Also similar to BALB/c mice, early-occurring adenosquamous mammary tumors were abundant among HFD-fed FVB mice. Tumors from HFD mice also had increased intra-tumor M2 macrophages. Prior to tumor development, HFD accelerated normal mammary gland development and increased mammary M2 macrophages, similarly to BALB/c mice. The promotional effects of puberty-initiated HFD on carcinogen-induced mammary cancer are thus largely weight gain-independent. Like BALB/c mice, HFD promoted adenosquamous tumors, suggesting a role for early age HFD in promoting this subtype of triple negative mammary cancer. M2 macrophage recruitment was common to both mouse strains. We speculate that a similar effect of HFD on immune function may contribute to epidemiological findings of increased breast cancer risk in young, premenopausal, normal-weight women who consume a diet high in saturated animal fat.